Biosign Announces Private Placement to Raise CDN $4.5 Million

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES


Biosign Technologies Inc. (CNSX:BIO) (the "Company" or "Biosign") today
announced that it intends to raise gross proceeds of up to CDN $4.5 million
through a brokered private placement of common shares of the Company (the
"Shares") at a price of 75 cents per common share (the "Offering"). The Company
has retained Dundee Securities Corporation to act as lead placement agent along
with Canaccord Financial Inc. as co-agent. 


Proceeds from the Offering are intended to be used as working capital to support
commercialization of the Company's products and services, with emphasis on
non-invasive monitoring of blood pressure and blood glucose, and for general
corporate purposes.


The Shares to be issued in connection with this Offering will be subject to a
four month hold period from the share issuance date in accordance with the
policies of the Canadian National Stock Exchange (CNSX Markets Inc.) and
applicable securities laws. The Offering is subject to all necessary regulatory
and stock exchange approvals. Closing of the Offering will be on or about March
25, 2010. 


About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent
systems for non-invasive monitoring of common health risks associated with blood
pressure, glucose, and medication. The core technology combines measurement,
analysis, and rapid knowledge formation to support health monitoring across
global markets. The UFIT(R) medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness, disease
state evaluation and management, and remote patient monitoring. For more
information on Biosign please visit http://www.biosign.com.


This news release does not constitute an offer to sell or a solicitation of an
offer to sell any of the securities in the United States. The securities have
not been and will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state securities laws and
may not be offered or sold within the United States or to U.S. persons unless
registered under the U.S. Securities Act and applicable state securities laws or
an exemption from such registration is available.